MicroRNA - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the micro RNA market size was valued at USD 3.00 billion in 2025 and estimated to grow from USD 3.45 billion in 2026 to reach USD 6.96 billion by 2031, at a CAGR of 15.05% during the forecast period (2026-2031).

This report Segments the Industry Into by Technology (Real Time Polymerase Chain Reaction, Microarray, Next Generation Sequencing (NGS), Immunoassay), by Application (Cancer, Immunological Disorder, Infectious Diseases, Cardiovascular Disease, and More), by End-User (Academic and Research Institutes, Biopharmaceutical Companies, Contract Research Organizations, and More) and Geography.

Global MicroRNA Market Trends and Insights

Rising prevalence of chronic & oncological diseases

Chronic illnesses continue to rise, with cancer alone causing 10 million deaths in 2024, amplifying demand for microRNA-based diagnostics and therapeutics . Emerging evidence shows microRNAs such as miR-4454 yielding an AUC of 0.889 for type 2 diabetes detection, spotlighting metabolic disease potential. Cardiovascular research indicates microRNAs regulating myocardial injury post-coronary microembolization, pointing to treatments beyond existing care. This widening disease spectrum reduces dependence on oncology and supports preventive medicine initiatives across aging populations in high-income countries and lifestyle-driven morbidity in emerging markets.

Rapid adoption of precision molecular diagnostics & liquid biopsy

Liquid biopsy assays using microRNA signatures now reach 90% sensitivity across nine cancers while maintaining 99% specificity. Non-invasive tests fill screening gaps for low-incidence yet deadly tumors such as pancreatic cancer; urinary miR-210-3p achieves 82.8% sensitivity and 74.3% specificity for early detection . Diagnostic centers integrate these assays alongside protein markers and imaging, accelerating routine adoption. AI-enhanced signature discovery shortens analysis time and boosts accuracy, granting first-mover advantage to laboratories embedding machine learning into data interpretation.

Delivery & stability challenges for miRNA therapeutics

Achieving tissue-specific delivery beyond the liver remains elusive. Lipid nanoparticles degrade rapidly in circulation, driving up dosage and toxicity. Single microRNAs modulate multiple pathways, demanding precision engineering to avoid unintended physiology. Research now pivots to ionizable polymer carriers and bioreducible linkers seeking enhanced pharmacokinetics. The technical gap delays broad systemic indications but spurs innovation among startups offering next-generation vehicles.

Other drivers and restraints analyzed in the detailed report include:

1. Intensifying R&D funding and strategic partnerships in miRNA therapeutics
2. Advancements in NGS & RT-qPCR platforms for small-RNA analysis
3. Regulatory fast-track / orphan-drug incentives for oligonucleotide drugs
4. AI-enabled multi-omics pipelines and exosome-based miRNA assays
5. Safety and off-target toxicity concerns

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Services held 47.78% micro RNA market share in 2025, equal to USD 1.43 billion of spending, as laboratories outsourced extraction, quantification, and bioinformatics workflows to contract research organizations (CROs). High capital barriers, talent shortages, and the rising complexity of multi-omic data interpretation encourage research institutes and biotech firms to tap external expertise rather than build internal capacity. CROs expand bundled offerings that marry wet-lab testing with AI-assisted analytics, reinforcing stickiness.

Kits & Reagents form the fastest-growing category at a 15.92% CAGR through 2031. Standardized, ready-to-use consumables shrink protocol variability and reduce turnaround time, enabling wider adoption by mid-tier clinical labs. Innovative silicon-carbide spin columns and magnetic bead chemistries improve yield and purity, supporting downstream NGS or RT-qPCR. Instruments remain essential for centralized core facilities, yet high unit costs and long replacement cycles temper growth. Major vendors refresh portfolios with modular upgrades-automated liquid handling, cloud-native software-that extend asset life while boosting throughput.

Real-Time PCR accounted for 38.25% of total revenue in 2025 due to regulatory familiarity, scalable throughput, and ease of use in clinical labs. Sensitivity continues to climb through LNA-enhanced primers and microfluidic chips capable of multiplexing dozens of targets per run.

Microarray platforms, although matured, log the highest 15.54% CAGR by offering economical whole-panel profiling for exploratory studies and circular RNA analyses where sequencing depth proves costly. Innovations in probe design and dye chemistry revive interest among academic researchers and CROs requiring large cohort screens. NGS gains ground through falling per-base costs on instruments such as NovaSeq X, which marry high throughput with flexible lane configurations suitable for both discovery and clinical validation use cases.

Complete Report Scope:

• By Product & Service
  • Kits & Reagents
  • Instruments
  • Services
• By Technology
  • Real-Time PCR
  • Microarray
  • Next-Generation Sequencing (NGS)
  • Immunoassay
  • Northern Blotting
  • In-situ Hybridization (ISH)
• By Application
  • Cancer
  • Cardiovascular Disease
  • Neurological Disease
  • Infectious Diseases
  • Immunological Disorders
  • Other Applications
• By End-User
  • Biopharmaceutical Companies
  • Diagnostic Centers
  • Hospitals & Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 41.72% of global revenue in 2025 underpinned by a mature biotechnology ecosystem, sizable NIH and venture funding, and FDA programs that prioritize innovative oligonucleotide therapeutics. Reimbursement frameworks covering liquid biopsy and companion diagnostics facilitate rapid hospital uptake.

Asia-Pacific is forecast as the fastest-growing region at 16.95% CAGR to 2031. Governments in China, Japan, and South Korea offer matching grants and tax incentives for RNA research infrastructure, while contract development and manufacturing organizations leverage cost-efficient supply chains to attract global sponsors. Rising chronic disease prevalence, together with aging demographics, lifts demand for early detection tests. Domestic firms tailor assays for hepatitis- and gastric cancer-heavy disease profiles, building regulatory pathways through National Medical Products Administration and Pharmaceuticals and Medical Devices Agency reforms.

Europe maintains strong market positioning through Horizon-funded consortia, sophisticated clinical trial networks, and cohesive data-protection rules that facilitate multi-center biomarker validation. ARTHEx Biotech's latest EUR 42 million round illustrates venture appetite for microRNA-targeting therapeutics headquartered in the region. Middle East & Africa and South America remain nascent but promising; increased expenditure on tertiary care hospitals and laboratory automation sets the foundation for gradually expanding microRNA diagnostics.

1. Thermo Fisher Scientific
2. QIAGEN
3. Illumina
4. Agilent Technologies
5. Merck
6. NanoString Technologies Inc.
7. Horizon Discovery
8. GeneCopoeia
9. OriGene Technologies
10. Norgen Biotek
11. Regulus Therapeutics Inc.
12. Miragen Therapeutics Inc.
13. Biorchestra Co. Ltd.
14. Mirxes Pte Ltd.
15. TransCode Therapeutics Inc.
16. Quantabio
17. Miltenyi Biotec
18. LGC Biosearch Technologies

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support